Organogenesis Named One of 50 Highest Growth Companies in Massachusetts by the Boston Business Journal

CANTON, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, has been named one of the Boston Business Journal’s (BBJ) Middle Market Leaders, a ranking of the 50 highest growth companies in Massachusetts.

“I am proud of the work we are doing at Organogenesis and that we have been recognized as a Middle Market Leader by the Boston Business Journal, achieving the rank of the 21^st highest growth company in Massachusetts,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. “This recognition is a testament to our market leadership and the dedication and determination of our employees to provide highly-innovative and effective integrated healing solutions that substantially improve the lives of patients while lowering the overall cost of health care.”

"We are pleased to once again honor these middle-market companies for their growth in the past few years," said Boston Business Journal Market President and Publisher Carolyn Jones. “These companies have shown durability and innovation in continuing to grow their businesses even during the challenges of the pandemic."

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as "will," "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," "extend," "continue" and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. Important factors that could cause actual outcomes to differ materially from those indicated by these forward-looking statements include risks and uncertainties described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Organogenesis cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only to the date of this release, and Organogenesis undertakes no obligations to update or revise these statements, except as may be required by law.

Press and Media Inquiries:
Lori Freedman
lfreedman@organo.com

Investor Inquiries:
Westwicke Partners
Mike Piccinino, CFA
OrganoIR@westwicke.com
443-213-0500